Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Status: Publicly traded
Direct answer
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is publicly traded on HKSE under the ticker 3378.HK.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa...
Can you invest in Hanx Biopharmaceuticals (Wuhan) Co., Ltd.?
Yes. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is publicly traded on HKSE under the ticker 3378.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Detailed equity research is provided by MarketSnap.